Company news

Verrica Pharmaceuticals Inc. news in 2021

Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.

View company

Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum

December 14, 2021

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

November 28, 2021

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

November 17, 2021

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 11, 2021

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

September 19, 2021

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 9, 2021

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

July 8, 2021

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

May 27, 2021

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

May 11, 2021

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

May 6, 2021

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

April 5, 2021

Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association

March 28, 2021

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan

March 16, 2021

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

March 3, 2021

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference

March 2, 2021

Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

February 16, 2021

Decks in 2021